Condition: Refractory and/or Relapsed Metastatic Solid Tumors · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
This description comes directly from the study's public registry record.
Heather Symons, MD, MHS · 410-502-4997 · hsymons2@jhmi.edu
Jasmine Brooks, BA · 667-306-8335 · jbrook54@jhmi.edu
Always discuss trial participation with your own doctor first.
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Albert Einstein College of Medicine, Children's Hospital at Montefiore | The Bronx, New York, United States | Recruiting |
| New York Medical Center/ Maria Fareri Children's Hospital | Valhalla, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01804634